FDA Extends Review of Ascendis Pharma's Navepegritide for Dwarfism Treatment

The US FDA has extended the review time of Ascendis Pharma's TransCon CNP (navepegritide) for achondroplasia treatment. The action date is now set for February 28, 2026, three months later than initially expected. The reason for the extension was not specified.